Healthcare Industry News: MRIdian
News Release - January 22, 2019
World's First MRIdian Center Celebrates Five Years of MRI-Guided Radiation TreatmentsSiteman Cancer Center Advances Precision Cancer Care through Presentations, Peer-Reviewed Publications and Pioneering Clinical Experience on its MRIdian Systems
CLEVELAND, Jan. 22, 2019 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY) announced today the five-year anniversary of patient treatments with MRIdian MRI-guided radiation therapy at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri.
As one of the world's leading cancer centers, Siteman is known for pioneering the advancement and adoption of innovative technologies with a focus on improving patient care and outcomes.
"We congratulate the Siteman team on reaching this milestone and commend them for their thought-leadership, innovation and commitment to cutting-edge cancer care," said Scott Drake, President and Chief Executive Officer of ViewRay. "As the first center to treat with MRIdian, they helped pave the way for the broader adoption of MRI-guided radiation therapy we're seeing today."
In January 2014, Siteman Cancer Center became the first center to treat patients using the world's first MRI-guided radiation therapy system – MRIdian by ViewRay. The center also was the first to perform adaptive radiation therapy under MRI-guidance, a practice that is now a routine part of treatment at Siteman. This adaptive therapy allows clinicians to adapt to changes and movement in the patient's anatomy in real-time while the patient is being treated, bringing greater precision to radiation delivery.
"The availability of a system capable of combining MRI and radiation therapy was an advance that the radiation oncology community had eagerly awaited, so we were thrilled to be the first to treat patients with the technology in 2014," said Jeff Michalski, M.D., Carlos A. Perez Distinguished Professor, Vice Chair and Director of Clinical Programs in Radiation Oncology at Siteman Cancer Center and Washington University School of Medicine. "The ability to track anatomical and tumor changes in real-time enables us to target tumors, while more precisely sparing healthy tissue. This technology greatly adds to the arsenal of cancer treatments we offer to patients."
In November 2017, Siteman acquired its second MRIdian System – the MRIdian Linac – following FDA-clearance of this next generation technology from ViewRay, which features MRI-guidance and linear accelerator delivery.
"The addition of both MRIdian systems has changed the way we deliver radiation. We can capture soft tissue images of the patient's body simultaneously during treatment. We can perform real-time contouring, optimization and quality assurance while the patient is being treated. We can treat tumors in close proximity to organs-at-risk, even using high-dose radiation," said Dennis E. Hallahan, M.D., FASTRO, Elizabeth H. and James S. McDonnell III Distinguished Professor of Medicine Chair, Department of Radiation Oncology at Washington University.
Over the past five years, the Siteman team has been active in sharing its clinical experience to advance the practice of MRI-guided radiation therapy. Clinicians from Siteman have presented more than 90 papers and posters at major medical meetings and published more than 40 studies in peer-reviewed medical journals, highlighting their experience with MRI-guided radiation therapy. The department is currently involved in four clinical trials to explore MRI-guided radiation therapy for pancreas, breast, lung, and spine. To date, the MRIdian system at Siteman Cancer Center has been used to treat more than 890 patients, 2,200 adaptive therapy sessions and more than 15 different indications.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Intended Use: The MRIdian Linac System, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.
Forward Looking Statements: This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to references to the recent study results, clinical trial results, related clinical experience and patient outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
ViewRay Partners with Leading Canadian Distributor to Bring MRI-guided Radiation Therapy to Canada
ViewRay Partners with Largest Independent Distributor in Australia and New Zealand to Bring Benefits of MRI-Guided Radiation Therapy to the Region